Developer docs
API playgroundTry for free, no card

Search company profiles

Zentiva Polska

Full company profile

uuid02lofkx

Namestring
Zentiva Polska
Legal namestring
Zentiva Polska Sp. z o.o.
Websiteurl
zentiva.pl
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Zentiva Polska Sp. z o.o. is the Polish operating subsidiary of Zentiva Group, a.s., a European pharmaceutical company that develops, manufactures, and distributes generic, biosimilar, and over-the-counter medicines across multiple therapeutic areas including cardiology, diabetology, pulmonology, oncology, neurology, gastroenterology, and urology. The Polish entity operates from its headquarters at 17 Bonifraterska Street, Warsaw, and is part of a broader group that serves more than 100 million patients in over 40 countries through 31 active subsidiaries, 6 branches, four owned manufacturing facilities, and an external production partner network. The group employs 5400+ people globally and 500+ in Poland, supported by a sales force of 1800+ medical representatives across Europe, with over 200 representatives operating in Poland.

Zentiva's core technology and operational backbone is a pharmaceutical Quality Management System aligned with ICH Q10 guidelines, supported by manufacturing facilities regularly inspected and approved by the EMA, MHRA, Swissmedic, and US FDA. The group's product portfolio includes prescription (Rx) generics, OTC medications, dietary supplements, biosimilars (developed in partnership with mAbxience and Lupin), and Consumer Healthcare products (recently expanded through the Aboca brands acquisition). Beyond finished-dose products, Zentiva monetizes its capabilities through two B2B platforms — Zent2U, which provides APIs, contract development and manufacturing (CDMO), and licensing services, and Prague Scientific, which offers formulation development, manufacturing, and pharmacovigilance services.

The business model is sales-led and diversified across multiple revenue streams: one-time sales of generic and OTC pharmaceuticals across 40+ European countries, professional services revenue from CDMO and development work, and licensing royalties. Go-to-market relies on direct engagement with physicians, pharmacists, and healthcare-system decision-makers through field sales representatives, complemented by pharmacy distribution partners and public tender procurement. Customer segments span healthcare professionals, retail and hospital pharmacies, public procurement agencies, distribution partners, and end patients. Pricing for prescription products is governed by national reimbursement systems across European markets, while OTC and B2B service pricing is determined by individual contract terms.

Short descriptiontext

Zentiva Polska is the Polish subsidiary of Zentiva Group, a European pharmaceutical company developing, manufacturing, and distributing generic, biosimilar, and OTC medicines across cardiology, oncology, neurology, urology, and other therapeutic areas for patients in Poland and across Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersWarsaw, Poland
HQ citystring
Warsaw
HQ countrystring
Poland
HQ regionstring
Europe
Markets served

Serves global market

Offices21 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, over-the-counter medicines, biosimilar products, contract development manufacturing, active pharmaceutical ingredients
Industry3 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRADAGAE
Specialty Condition Supplements (Sleep, Stress, Heart, Joint, Gut, Immunity)
NAICS code4 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
  • Medicinal and Botanical Manufacturing325411
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Generic Pharmaceuticals
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Generic Pharmaceuticals Sales
TypeOne Time License
Description

Core revenue from development, manufacturing and distribution of high-quality, affordable generic medicines across 40+ countries in Europe. Portfolio includes prescription (Rx) and over-the-counter (OTC) medications plus dietary supplements.

zentiva.pl
2Contract Manufacturing (CDMO)
TypeProfessional Services
Description

Zent2U platform provides comprehensive B2B support including active pharmaceutical ingredients (API), contract development and manufacturing services, and licensing. Manufacturing capabilities offered through own facilities.

zentiva.pl
3Licensing and Outlicensing
TypeLicensing Royalties
Description

Licensing services through Zent2U and Prague Scientific platforms, offering development and scientific services supporting product lifecycle from concept to regulatory maintenance.

zentiva.pl
4Consumer Healthcare Products
TypeOne Time License
Description

Portfolio of Consumer Healthcare products, particularly strengthened in Czech Republic, Romania, and Slovakia through Aboca brand acquisition.

zentiva.pl
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure
Pricing details1 tier
1Prescription (Rx) and Over-the-Counter (OTC) products
ModelOtherBilling cadenceMulti-year contract
Notes

Public reimbursement pricing governed by national health authorities. OTC products available at retail pharmacy pricing.

zentiva.pl
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Zent2U
Description

B2B business platform offering access to APIs, CDMO services, and licensing

zentiva.pl
+2 more records
Core offering1 text field

Zentiva Polska develops, markets, and supplies a broad portfolio of generic prescription (Rx) and over-the-counter (OTC) medicines, biosimilars, and dietary supplements across key therapeutic areas including cardiology, diabetology, oncology, respiratory, neurology, urology, and gastroenterology. As the Polish subsidiary of Zentiva Group, it distributes over 50 medicinal products in Poland through pharmacy and distribution partners, complemented by the group's B2B platforms (Zent2U for APIs, CDMO, and licensing; Prague Scientific for development services).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 100 million+ people served across 40+ European countries
+4 more records
Product overview1 text field

Zentiva Polska is the Polish subsidiary of Zentiva Group, a leading European pharmaceutical company specializing in generic medicines, specialist products, and consumer healthcare. The company operates a unified portfolio combining prescription medications (Rx), over-the-counter products (OTC), and dietary supplements across key therapeutic areas including cardiology, diabetology, oncology, pulmonology, neurology, urology, and gastroenterology. The portfolio is complemented by B2B service platforms (Zent2U for API, CDMO, and licensing; Prague Scientific for development services) and patient support programs. The Polish operation distributes over 50 medicinal products, with the broader group serving over 100 million people in more than 40 countries through four manufacturing facilities and a network of production partners.

Product and service7 records
1Generic Medicines Portfolio
CategoryGeneric Pharmaceuticals
Description

Broad portfolio of generic pharmaceuticals covering cardiovascular, oncology, respiratory, neurological, urological, musculoskeletal, and digestive therapeutic areas. Includes prescription (Rx) and over-the-counter (OTC) medications as well as dietary supplements available through pharmacy and distribution channels in Poland.

2Consumer Healthcare Products
CategoryConsumer Healthcare
Description

Portfolio of consumer healthcare products based on natural ingredients, including acquired Aboca brands. Distributed through retail pharmacy channels for direct consumer use.

3Added-Value Medicines
CategoryGeneric Pharmaceuticals
Description

Bioequivalent medicines and value-added solutions with modern formulations, integrating green design principles and new technologies for differentiated patient and prescriber value.

4Zent2U B2B Platform
CategoryPharmaceutical Services
Description

B2B platform offering access to active pharmaceutical ingredients (APIs), contract development and manufacturing (CDMO) services, and out-licensing. Specializes in cardiology, urology, oncology, neurology, and hormone therapies for third-party pharmaceutical partners.

5Prague Scientific
CategoryPharmaceutical Services
Description

Development and scientific services supporting every stage of pharmaceutical product lifecycle from concept through regulatory maintenance, including active ingredient and formulation development, manufacturing in eco-friendly facilities, and pharmacovigilance activities.

6Patient Support Programs - Urology
CategoryPatient Services
Description

Educational programs for patients regarding benign prostatic hyperplasia (BPH), prostate cancer, and overactive bladder (OAB). Includes specialist consultations, knowledge assessments, and educational materials developed by experts.

7Zentiva dla Pacjenta - Patient Education Portal
CategoryPatient Services
Description

Patient-facing educational portal covering therapeutic areas including urology, psychiatry, neurology, cardiology, pulmonology, and allergology, with expert-authored articles and health guidance for Polish patients.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-07-09
Description

License and supply agreement for a biosimilar TNF alpha inhibitor. Zentiva and Lupin collaboration expands biosimilar portfolio.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Acquisition of recognized brands from Aboca strengthening Consumer Healthcare portfolio with natural ingredient-based products for consumers across Europe.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

License agreement with Adalvo covering respiratory, CNS, and dermatology therapeutic areas.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

First biosimilar product launch through collaboration with mAbxience. Product launched in 21 European countries.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Acquisition of Creo Pharmaceuticals in United Kingdom expanding European presence.

6Solacium Pharma
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Acquisition of Solacium Pharma in Romania strengthening regional presence.

zentiva.pl
7Alvogen CEE
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Acquisition of Alvogen operations in Central and Eastern Europe expanding generic pharmaceutical portfolio.

zentiva.pl
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic collaboration through international research platform supporting pharmaceutical innovation and development.

Strategic tierCoreTypeOthers
Description

Active membership with participation in governance, supervisory board, and thematic groups. Applies Medicines for Europe Code of Conduct ensuring ethical marketing practices. Leading organization for generic pharmaceutical companies responsible for largest share of medicine deliveries in Europe.

Strategic tierMinorTypeOthers
Description

Membership in Advisory and Support Group engaging in EU industrial policy shaping with focus on medicine production security and supply chains.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Campaign partner in 'Swiat w twoich rekach' (World in Your Hands) initiative for proper pharmaceutical waste disposal and patient adherence education. Part of NEUCA Group.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Campaign partner in pharmaceutical waste disposal and adherence education campaign alongside other leading Polish pharmaceutical companies.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Campaign partner in pharmaceutical waste disposal and adherence education campaign.

14Zaklady Farmaceutyczne Polpharma S.A.
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Campaign partner in pharmaceutical waste disposal and adherence education campaign.

zentiva.pl
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Polish private pharmaceutical group operating in generics, OTC and specialty. Comparable Polish-market positioning and a co-campaign partner with Zentiva in patient-adherence and disposal initiatives.

2Sandoz (Novartis)
TypeDirect peer
Description

European-headquartered generics and biosimilars business spun out of Novartis. Closest direct competitor to Zentiva in European generics, with comparable geographic footprint, biosimilar portfolio and CDMO-style B2B service offering.

TypeDirect peer
Description

Global leader in generic and specialty pharmaceuticals with deep European commercial coverage. Highly comparable business model of high-volume generics plus selected specialty/biosimilar exposure, and similar reliance on tender and reimbursement channels across Europe.

TypeDirect peer
Description

Global generics and specialty pharma company formed from Mylan and Upjohn. Comparable generic-pharma economics, broad European presence, and growing biosimilars franchise that mirrors Zentiva's strategic direction.

TypeDirect peer
Description

Privately-held European generics and consumer healthcare company with strong German and CEE presence. Comparable portfolio mix of generics, OTC and biosimilars, and similar PE-ownership history.

TypeDirect peer
Description

Hungarian-origin specialty and generic pharmaceutical group with strong CEE footprint and European commercial reach. Comparable in generics plus specialty/biosimilar adjacency and CEE manufacturing base.

TypeEmerging player
Description

Indian-headquartered global generics and biosimilars manufacturer and Zentiva's biosimilar partner (TNF alpha inhibitor licensing deal). Comparable in biosimilar development and global generics ambitions, though with lower European commercial depth.

TypeDirect peer
Description

Slovenian-headquartered generics manufacturer with leading Central and Eastern European market share. Highly comparable in therapeutic-area coverage, geographic mix and reliance on CEE tender markets.

TypeDirect peer
Description

Poland's largest pharmaceutical manufacturer and a Zentiva co-campaign partner ('Świat w twoich rękach'). Directly competes with Zentiva Polska across generic and OTC categories in the Polish market.

TypeDirect peer
Description

Central and Eastern European-focused generics group; Zentiva acquired Alvogen's CEE operations in 2019. Directly comparable product mix and CEE commercial footprint.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries36 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Zentiva Polska

Generic Pharmaceuticalszentiva.pl

Zentiva Polska is the Polish subsidiary of Zentiva Group, a European pharmaceutical company developing, manufacturing, and distributing generic, biosimilar, and OTC medicines across cardiology, oncology, neurology, urology, and other therapeutic areas for patients in Poland and across Europe.

What Zentiva Polska does

Zentiva Polska Sp. z o.o. is the Polish operating subsidiary of Zentiva Group, a.s., a European pharmaceutical company that develops, manufactures, and distributes generic, biosimilar, and over-the-counter medicines across multiple therapeutic areas including cardiology, diabetology, pulmonology, oncology, neurology, gastroenterology, and urology. The Polish entity operates from its headquarters at 17 Bonifraterska Street, Warsaw, and is part of a broader group that serves more than 100 million patients in over 40 countries through 31 active subsidiaries, 6 branches, four owned manufacturing facilities, and an external production partner network. The group employs 5400+ people globally and 500+ in Poland, supported by a sales force of 1800+ medical representatives across Europe, with over 200 representatives operating in Poland.

Zentiva's core technology and operational backbone is a pharmaceutical Quality Management System aligned with ICH Q10 guidelines, supported by manufacturing facilities regularly inspected and approved by the EMA, MHRA, Swissmedic, and US FDA. The group's product portfolio includes prescription (Rx) generics, OTC medications, dietary supplements, biosimilars (developed in partnership with mAbxience and Lupin), and Consumer Healthcare products (recently expanded through the Aboca brands acquisition). Beyond finished-dose products, Zentiva monetizes its capabilities through two B2B platforms — Zent2U, which provides APIs, contract development and manufacturing (CDMO), and licensing services, and Prague Scientific, which offers formulation development, manufacturing, and pharmacovigilance services.

The business model is sales-led and diversified across multiple revenue streams: one-time sales of generic and OTC pharmaceuticals across 40+ European countries, professional services revenue from CDMO and development work, and licensing royalties. Go-to-market relies on direct engagement with physicians, pharmacists, and healthcare-system decision-makers through field sales representatives, complemented by pharmacy distribution partners and public tender procurement. Customer segments span healthcare professionals, retail and hospital pharmacies, public procurement agencies, distribution partners, and end patients. Pricing for prescription products is governed by national reimbursement systems across European markets, while OTC and B2B service pricing is determined by individual contract terms.

Zentiva Polska firmographics

Firmographics
Name
Zentiva Polska
Legal name
Zentiva Polska Sp. z o.o.
Website
https://zentiva.pl
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
101–250 employees
Short description
Zentiva Polska is the Polish subsidiary of Zentiva Group, a European pharmaceutical company developing, manufacturing, and distributing generic, biosimilar, and OTC medicines across cardiology, oncology, neurology, urology, and other therapeutic areas for patients in Poland and across Europe.
Ownership category
akta.pro rank

Zentiva Polska industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRADAGAE
Specialty Condition Supplements (Sleep, Stress, Heart, Joint, Gut, Immunity)

Keywords

  • Generic pharmaceuticals
  • Over-the-counter medicines
  • Biosimilar products
  • Contract development manufacturing
  • Active pharmaceutical ingredients

Where Zentiva Polska is headquartered

Location

Headquarters

HQ city
Warsaw
HQ country
Poland
HQ region
Europe

Offices21 records

Markets served

Zentiva Polska business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Generic Pharmaceuticals Sales: Core revenue from development, manufacturing and distribution of high-quality, affordable generic medicines across 40+ countries in Europe. Portfolio includes prescription (Rx) and over-the-counter (OTC) medications plus dietary supplements.
  2. Contract Manufacturing (CDMO): Zent2U platform provides comprehensive B2B support including active pharmaceutical ingredients (API), contract development and manufacturing services, and licensing. Manufacturing capabilities offered through own facilities.
  3. Licensing and Outlicensing: Licensing services through Zent2U and Prague Scientific platforms, offering development and scientific services supporting product lifecycle from concept to regulatory maintenance.
  4. Consumer Healthcare Products: Portfolio of Consumer Healthcare products, particularly strengthened in Czech Republic, Romania, and Slovakia through Aboca brand acquisition.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractPrescription (Rx) and Over-the-Counter (OTC) products

Go-to-market motion3 records

Distribution channels5 records

Marketing channels9 records

Zentiva Polska product offering

Product offering

Core offering

Zentiva Polska develops, markets, and supplies a broad portfolio of generic prescription (Rx) and over-the-counter (OTC) medicines, biosimilars, and dietary supplements across key therapeutic areas including cardiology, diabetology, oncology, respiratory, neurology, urology, and gastroenterology. As the Polish subsidiary of Zentiva Group, it distributes over 50 medicinal products in Poland through pharmacy and distribution partners, complemented by the group's B2B platforms (Zent2U for APIs, CDMO, and licensing; Prague Scientific for development services).

Product overview

Zentiva Polska is the Polish subsidiary of Zentiva Group, a leading European pharmaceutical company specializing in generic medicines, specialist products, and consumer healthcare. The company operates a unified portfolio combining prescription medications (Rx), over-the-counter products (OTC), and dietary supplements across key therapeutic areas including cardiology, diabetology, oncology, pulmonology, neurology, urology, and gastroenterology. The portfolio is complemented by B2B service platforms (Zent2U for API, CDMO, and licensing; Prague Scientific for development services) and patient support programs. The Polish operation distributes over 50 medicinal products, with the broader group serving over 100 million people in more than 40 countries through four manufacturing facilities and a network of production partners.

Differentiator

Problem solved

Functional benefit

Brands

  • Zent2U: B2B business platform offering access to APIs, CDMO services, and licensing
  • Prague Scientific
  • Zentiva Stars

Products and services

  • Generic Medicines Portfolio Broad portfolio of generic pharmaceuticals covering cardiovascular, oncology, respiratory, neurological, urological, musculoskeletal, and digestive therapeutic areas. Includes prescription (Rx) and over-the-counter (OTC) medications as well as dietary supplements available through pharmacy and distribution channels in Poland.
  • Consumer Healthcare Products Portfolio of consumer healthcare products based on natural ingredients, including acquired Aboca brands. Distributed through retail pharmacy channels for direct consumer use.
  • Added-Value Medicines Bioequivalent medicines and value-added solutions with modern formulations, integrating green design principles and new technologies for differentiated patient and prescriber value.
  • Zent2U B2B Platform B2B platform offering access to active pharmaceutical ingredients (APIs), contract development and manufacturing (CDMO) services, and out-licensing. Specializes in cardiology, urology, oncology, neurology, and hormone therapies for third-party pharmaceutical partners.
  • Prague Scientific Development and scientific services supporting every stage of pharmaceutical product lifecycle from concept through regulatory maintenance, including active ingredient and formulation development, manufacturing in eco-friendly facilities, and pharmacovigilance activities.
  • Patient Support Programs - Urology Educational programs for patients regarding benign prostatic hyperplasia (BPH), prostate cancer, and overactive bladder (OAB). Includes specialist consultations, knowledge assessments, and educational materials developed by experts.
  • Zentiva dla Pacjenta - Patient Education Portal Patient-facing educational portal covering therapeutic areas including urology, psychiatry, neurology, cardiology, pulmonology, and allergology, with expert-authored articles and health guidance for Polish patients.

Quantifiable outcome

  • 100 million+ people served across 40+ European countries
  • +4 more outcomes

Companies that use Zentiva Polska

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Zentiva Polska technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Zentiva Polska partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered major, minor and core.

  • LupinmajorStrategic or Co-development Partner · 9 July 2025License and supply agreement for a biosimilar TNF alpha inhibitor. Zentiva and Lupin collaboration expands biosimilar portfolio.
  • AbocamajorStrategic or Co-development Partner · 1 January 2025Acquisition of recognized brands from Aboca strengthening Consumer Healthcare portfolio with natural ingredient-based products for consumers across Europe.
  • AdalvomajorStrategic or Co-development Partner · 1 January 2023License agreement with Adalvo covering respiratory, CNS, and dermatology therapeutic areas.
  • mAbxiencemajorStrategic or Co-development Partner · 1 January 2021First biosimilar product launch through collaboration with mAbxience. Product launched in 21 European countries.
  • Creo Pharmaceuticals LtdmajorStrategic or Co-development Partner · 1 January 2019Acquisition of Creo Pharmaceuticals in United Kingdom expanding European presence.
  • Solacium PharmamajorStrategic or Co-development Partner · 1 January 2019Acquisition of Solacium Pharma in Romania strengthening regional presence.
  • Alvogen CEEmajorStrategic or Co-development Partner · 1 January 2019Acquisition of Alvogen operations in Central and Eastern Europe expanding generic pharmaceutical portfolio.
  • PARC (Pharmaceutical Applied Research Centre)minorStrategic or Co-development PartnerAcademic collaboration through international research platform supporting pharmaceutical innovation and development.
  • Medicines for EuropecoreOthersActive membership with participation in governance, supervisory board, and thematic groups. Applies Medicines for Europe Code of Conduct ensuring ethical marketing practices. Leading organization for generic pharmaceutical companies responsible for largest share of medicine deliveries in Europe.
  • BusinessEuropeminorOthersMembership in Advisory and Support Group engaging in EU industrial policy shaping with focus on medicine production security and supply chains.
  • Swiat Zdrowia S.A.minorStrategic or Co-development PartnerCampaign partner in 'Swiat w twoich rekach' (World in Your Hands) initiative for proper pharmaceutical waste disposal and patient adherence education. Part of NEUCA Group.
  • Adamed PharmaminorStrategic or Co-development PartnerCampaign partner in pharmaceutical waste disposal and adherence education campaign alongside other leading Polish pharmaceutical companies.
  • Teva Pharmaceuticals PolskaminorStrategic or Co-development PartnerCampaign partner in pharmaceutical waste disposal and adherence education campaign.
  • Zaklady Farmaceutyczne Polpharma S.A.minorStrategic or Co-development PartnerCampaign partner in pharmaceutical waste disposal and adherence education campaign.

Scale indicators15 records

Recent moves7 records

Expansion highlights6 records

Zentiva Polska competitors and assessment

Company assessment

Direct peers

  • Adamed Pharma: Polish private pharmaceutical group operating in generics, OTC and specialty. Comparable Polish-market positioning and a co-campaign partner with Zentiva in patient-adherence and disposal initiatives.
  • Sandoz (Novartis): European-headquartered generics and biosimilars business spun out of Novartis. Closest direct competitor to Zentiva in European generics, with comparable geographic footprint, biosimilar portfolio and CDMO-style B2B service offering.
  • Teva Pharmaceutical Industries: Global leader in generic and specialty pharmaceuticals with deep European commercial coverage. Highly comparable business model of high-volume generics plus selected specialty/biosimilar exposure, and similar reliance on tender and reimbursement channels across Europe.
  • Viatris: Global generics and specialty pharma company formed from Mylan and Upjohn. Comparable generic-pharma economics, broad European presence, and growing biosimilars franchise that mirrors Zentiva's strategic direction.
  • Stada Arzneimittel: Privately-held European generics and consumer healthcare company with strong German and CEE presence. Comparable portfolio mix of generics, OTC and biosimilars, and similar PE-ownership history.
  • Gedeon Richter: Hungarian-origin specialty and generic pharmaceutical group with strong CEE footprint and European commercial reach. Comparable in generics plus specialty/biosimilar adjacency and CEE manufacturing base.
  • Krka: Slovenian-headquartered generics manufacturer with leading Central and Eastern European market share. Highly comparable in therapeutic-area coverage, geographic mix and reliance on CEE tender markets.
  • Polpharma: Poland's largest pharmaceutical manufacturer and a Zentiva co-campaign partner ('Świat w twoich rękach'). Directly competes with Zentiva Polska across generic and OTC categories in the Polish market.
  • Alvogen: Central and Eastern European-focused generics group; Zentiva acquired Alvogen's CEE operations in 2019. Directly comparable product mix and CEE commercial footprint.

Emerging players

  • Lupin: Indian-headquartered global generics and biosimilars manufacturer and Zentiva's biosimilar partner (TNF alpha inhibitor licensing deal). Comparable in biosimilar development and global generics ambitions, though with lower European commercial depth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Zentiva Polska social profiles

Digital presence

Zentiva Polska compliance and trust

Trust signal

Compliance9 records

Zentiva Polska financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Zentiva Polska leadership team

Management profile

Number of profiles

Zentiva Polska subsidiaries and ownership

Company hierarchy

Subsidiaries36 records

Zentiva Polska funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Zentiva Polska M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zentiva Polska

What does Zentiva Polska do?

Zentiva Polska develops, markets, and supplies a broad portfolio of generic prescription (Rx) and over-the-counter (OTC) medicines, biosimilars, and dietary supplements across key therapeutic areas including cardiology, diabetology, oncology, respiratory, neurology, urology, and gastroenterology. As the Polish subsidiary of Zentiva Group, it distributes over 50 medicinal products in Poland through pharmacy and distribution partners, complemented by the group's B2B platforms (Zent2U for APIs, CDMO, and licensing; Prague Scientific for development services).

Is Zentiva Polska a public or private company?

Zentiva Polska is a private company. It is classified as private equity controlled and is currently operating.

When was Zentiva Polska founded?

Zentiva Polska was founded in 2003. It employs 101 to 250 people.

Where is Zentiva Polska based?

Zentiva Polska is headquartered in Warsaw, Poland, in the Europe region.

How does Zentiva Polska make money?

Four revenue lines are on record. Generic Pharmaceuticals Sales are the primary driver. The others are contract Manufacturing (CDMO), licensing and Outlicensing and consumer Healthcare Products.

Who are Zentiva Polska's main competitors?

Direct peers on record are Adamed Pharma, Sandoz (Novartis), Teva Pharmaceutical Industries, Viatris, Stada Arzneimittel, Gedeon Richter, Krka, Polpharma and Alvogen. Lupin is listed as an emerging player.

Does Zentiva Polska have an API?

No public API is recorded for Zentiva Polska.

What industry is Zentiva Polska in?

Zentiva Polska's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales